rdy+acl will ruin gsk , page-2

Dont be surprised once RDY & ACL reports better than expected sales !!!

http://alchemia.com.au/irm/content/products.html

Dr Reddy's has extensive scale-up and manufacturing capacity and broad regulatory experience with ANDA filings. In addition, Dr Reddy's has a generics focus with increasing sales in the US. In the past two years Dr Reddy's has driven the growth of its generic business with the acquisition of the Betapharm Group in Germany and Roche's state-of-the-art active pharmaceutical ingredient (API) manufacturing plant in Mexico. As a bulk manufacturer, Dr Reddy's is able to produce fondaparinux at an extremely competitive price, addressing the need to maintain pressure on cost of goods in a generic environment.